Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Fouad Namouni, head of R&D at Blueprint Medicines, discusses how dual blockade of a single target could push the tyrosine kinase inhibitor envelope.Nature Reviews Drug Discovery, Published online: 2022-05-17; doi:10.1038/d41573-022-00091-52022-05-17 DOI: 10.1038/d41573-022-00091-5
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
A PARP1-selective drug and a pipeline of ATR inhibitors demonstrate the near-term opportunities and long-term challenges for synthetic lethality in anticancer drug development.Nature Reviews Drug Discovery, Published online: 2022-05-17; doi:10.1038/d41573-022-00092-42022-05-17 DOI: 10.1038/d41573-022-00092-4
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
FDA approves first cardiac myosin inhibitorNature Reviews Drug Discovery, Published online: 2022-05-10; doi:10.1038/d41573-022-00087-12022-05-10 DOI: 10.1038/d41573-022-00087-1
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pull incentives for antibiotics get push from the UKNature Reviews Drug Discovery, Published online: 2022-05-10; doi:10.1038/d41573-022-00088-02022-05-10 DOI: 10.1038/d41573-022-00088-0
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billionNature Reviews Drug Discovery, Published online: 2022-05-10; doi:10.1038/d41573-022-00090-62022-05-10 DOI: 10.1038/d41573-022-00090-6
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Bispecific antibodies pin down cancer stem cellsNature Reviews Drug Discovery, Published online: 2022-05-10; doi:10.1038/d41573-022-00086-22022-05-10 DOI: 10.1038/d41573-022-00086-2
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Probing the antidepressant action of psychedelicsNature Reviews Drug Discovery, Published online: 2022-05-09; doi:10.1038/d41573-022-00085-32022-05-09 DOI: 10.1038/d41573-022-00085-3
Subscription journal
